Early TIPS for Advanced Liver Cancer with Vein Blockage
Part of Cancer, Digestive system clinical trials.
This study tests whether placing a small tube (TIPS) early in people with advanced liver cancer and a vein blockage helps their other treatments work better. It is for patients who are already taking lenvatinib and immunotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with hepatocellular carcinoma (liver cancer) with a tumor in the main vein of your liver.
- You have had a procedure called TIPS to reduce pressure in your liver within the last 72 hours.
- You are taking lenvatinib and a PD-1 inhibitor (immunotherapy) as your first cancer treatment.
- Your liver function is good enough (Child-Pugh A or B) and you are able to do daily activities (ECOG 0-2).
- You have no more than five tumors in your liver and no more than two other organs with limited spread.
- Your blood counts and kidney and liver tests are within safe limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a TIPS stent graft (a tiny mesh tube placed in the liver to relieve pressure) for people with cirrhosis and complications like bleeding or fluid buildup. It aims to see how well it works and if it's safe.
This Phase 3 trial tests whether combining several treatments—SBRT (targeted radiation), lenvatinib (an oral anti-cancer medicine), and TACE (a procedure that blocks blood supply to the tumor)—can work better for people with advanced primary liver cancer. It may help shrink tumors and improve survival compared with standard approaches.
This study tests whether a combination of the drug lenvatinib, a liver treatment called TACE, and the immunotherapy drug camrelizumab can shrink advanced hepatocellular carcinoma enough to make surgery (or “conversion resection”) possible. It may help some people live longer by improving the chance that the cancer can be removed.
This study tests a new version of a device (VIATORR TIPS) that helps lower high blood pressure in the liver for people with cirrhosis. The device is placed to create a small channel that reroutes blood flow and reduces pressure.
This trial combines a procedure called TIPS (which helps relieve pressure in the liver) with two drugs—lenvatinib (a targeted therapy) and a PD-1 inhibitor (an immunotherapy)—for people with advanced liver cancer that has spread into the main vein of the liver. It aims to see if this combination can help control the cancer and improve symptoms.
This trial tests a combination of targeted therapy (lenvatinib), immunotherapy (PD-1 inhibitor), and a procedure called TACE (which delivers chemotherapy directly to the liver tumor) for people whose liver cancer has ruptured. The goal is to stop bleeding and shrink the tumor.
Hear when a new Advanced Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.